BOSTON SCIENTIFIC CORPORATION Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31)
BOSTON SCIENTIFIC CORPORATION (BSX) had Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31) of $97.00 million as of 2012-03-31, per its 10-Q filed 2012-05-03.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionPurchasePriceAllocationAmortizableIntangibleAssets · last filed 2013-05-29
- 2012-03-31: Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31) $97.00M.
- 2011-12-31: Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31) $97.00M.
- 2011-09-30: Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31) $97.00M.
- 2011-06-30: Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31) $54.00M.
| Period end | Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets (Deprecated 2013-01-31) |
|---|---|
| 2012-03-31 | $97.00M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $97.00M 10-K · filed 2012-02-17 |
| 2011-09-30 | $97.00M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $54.00M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $175.00M 8-K · filed 2013-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |